Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
GoldInxs Commences Maiden Drill Program at the Fishpot Project, Testing Multiple Gold-Silver and Copper-Gold Targets
